Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE – Get a rating) – Stock analysts Wedbush dropped their FY2026 EPS estimates for shares of Ultragenyx Pharmaceutical in a note to investors Thursday, October 13. Wedbush analyst L. Chico now expects the biopharmaceutical company to post earnings of $1.06 per share for the year, down from its previous estimate of $1.15. Wedbush currently has a “Neutral” rating on the title. The consensus estimate for Ultragenyx Pharmaceutical’s current annual earnings is ($8.45) per share.
A number of other stock analysts also commented on the stock. Evercore ISI cut its price target on shares of Ultragenyx Pharmaceutical to $60.00 in a Tuesday, August 9 report. Stifel Nicolaus cut his price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating for the company in a research note on Friday, July 1. Barclays lowered its price target on shares of Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday July 29 research note. StockNews.com began covering shares of Ultragenyx Pharmaceutical in a report on Wednesday. They set a “sell” rating for the company. Finally, Citigroup lowered its price target on Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, August 3 report. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned the stock a buy rating. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $106.92.
Ultragenyx Pharmaceutical Trading up 3.1%
NASDAQ RARE opened at $39.65 on Friday. The stock has a market capitalization of $2.78 billion, a P/E ratio of -5.42 and a beta of 1.24. The company’s fifty-day simple moving average is $46.38 and its 200-day simple moving average is $55.95. Ultragenyx Pharmaceutical has a 52 week low of $36.86 and a 52 week high of $89.56.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last announced its results on Thursday, July 28. The biopharmaceutical company reported ($2.26) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.54). The company posted revenue of $89.34 million for the quarter, versus $87.33 million expected by analysts. Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company’s quarterly revenue increased 2.7% from the same quarter last year. In the same quarter a year earlier, the company posted ($1.45) earnings per share.
Ultragenyx Pharmaceutical Institutional Trading
A number of institutional investors have recently changed their positions in the stock. State Street Corp increased its stake in Ultragenyx Pharmaceutical by 26.1% during the second quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company worth $146,603,000 after buying an additional 508,624 shares last quarter. Wellington Management Group LLP increased its stake in shares of Ultragenyx Pharmaceutical by 17.1% in Q1. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company worth $244,747,000 after buying an additional 492,842 shares last quarter. Rock Springs Capital Management LP increased its stake in Ultragenyx Pharmaceutical by 16.3% during the first quarter. Rock Springs Capital Management LP now owns 1,028,109 shares of the biopharmaceutical company valued at $74,661,000 after buying an additional 144,188 shares last quarter. Dimensional Fund Advisors LP increased its holdings in Ultragenyx Pharmaceutical by 44.1% during the first quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company worth $33,693,000 after acquiring an additional 141,945 shares during the period. Finally, Peregrine Capital Management LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth approximately $9,121,000. 88.27% of the shares are held by institutional investors and hedge funds.
About Ultranyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here